Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.
Aspen Pharmacare is part of Aspen Holdings which also has nutritional and fine chemical divisions.
Built upon a 160 year history Aspen Pharmacare has over 8000 employees and supplies products to over 150 countries globally. It has an OTC and consumer division that focus on areas such as self-medication, personal care and infant nutritionals.
Aspen Pharmacare’s products treat a vast array of therapeutic areas including pain management, cardiovascular, gastrointestinal, oncology, musculoskeletal, respiratory and urinary. The company is also South Africa’s leading provider of anti-retrovirals (ARV’s) for the treatment of HIV. Back in 2003 it was the first company to launch generic ARV’s.
Aspen’s leading prescription brands include
- Aspen Lamzid,
- Aspen Meropenem,
- Dutch Medicines,
Manufacturing takes place in 17 facilities based around the world at sites including Australia, Kenya, Brazil, Mexico and Germany. With such a strong global presence, Aspen is target for many companies for partnering.
Signing major deals
Over the past 5 years Aspen Pharmacare has signed 18 partnering deals, a fair few of these deals have been with GlaxoSmithKine; in October 2014 GSK took a 25% stake in Aspen Pharmacare’s Japanese unit in a bid to increase commercial operations in the Asian country and in September 2013 Aspen acquired the Arixtra and Fraxiparine/Fraxodi brands from GSK as well as a specialised sterile production site worth $700m. As a long term partner of GSK, Aspen Pharmacare were entrusted with responsibility of taking the products forward.
Aspen Pharmacare has also partnered with Merck and Co., Nestle, Cipla, Roche and Eli Lilly, proving that it has truly cemented its position in the global market as a supplier and partner of choice.
Aspen is often present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Aspen presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Aspen in person visit Current Partnering’s Event calendar.
Contacting Aspen for partnering
Aspen can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Aspen Kabi’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at Aspen’ website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Aspen’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Aspen LinkedIn page here.
Aspen Pharma partnering at Current Agreements
Full details on each deal can be found at Current Agreements (subscription required)
Or purchase report: Partnering Agreements with Aspen Pharma 2009-2014
No M&A activity for Aspen Pharma
Related reports from Current Partnering
Report: Partnering Agreements with Aspen Pharma 2009-2014
Available resources for deal coverage for Aspen Pharma
Read: more on Aspen Pharma company profile, recent partnering, M&A and financing news and articles
Report: Finding Biopharma Licensing and Collaboration Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk